# TOP-Study (Tacrolimus Organ Perfusion): Treatment of Ischemia Reperfusion Injury in Marginal Organs With an ex Vivo Tacrolimus Perfusion

> **NCT01564095** · PHASE2,PHASE3 · TERMINATED · sponsor: **Ludwig-Maximilians - University of Munich** · enrollment: 25 (actual)

## Conditions studied

- Terminal Liver Disease
- Ischemia Reperfusion Injury
- Graft Dysfunction
- Graft Failure
- Poor Graft Quality

## Interventions

- **DRUG:** Tacrolimus
- **DRUG:** HTK/Placebo

## Key facts

- **NCT ID:** NCT01564095
- **Lead sponsor:** Ludwig-Maximilians - University of Munich
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-10
- **Primary completion:** 2013-07
- **Final completion:** 2013-07
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** Missing evidence of the effectiveness of the study medication
- **Last updated:** 2017-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01564095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01564095, "TOP-Study (Tacrolimus Organ Perfusion): Treatment of Ischemia Reperfusion Injury in Marginal Organs With an ex Vivo Tacrolimus Perfusion". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT01564095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*